GRI BIO (NASDAQ: GRI) is a dynamic clinical-stage biotechnology company at the forefront of revolutionizing healthcare through groundbreaking scientific advancements. The company is focused on fundamentally changing how inflammatory, fibrotic and autoimmune diseases are treated.
Category
🗞
NewsTranscript
00:00 (upbeat music)
00:02 GRI Bio, trading on the NASDAQ under the ticker GRI,
00:05 is a dynamic and promising clinical stage
00:08 biotechnology company at the forefront
00:10 of revolutionizing healthcare
00:11 through groundbreaking scientific advancements.
00:14 The company is focused on fundamentally changing
00:16 how inflammatory, fibrotic,
00:18 and autoimmune diseases are treated.
00:20 GRI is led by an expert team of executives
00:22 with years of experience
00:23 leading successful biotech companies.
00:26 The combination of business acumen
00:27 and leading scientific research
00:29 makes GRI's efforts to change
00:30 the inflammatory therapy landscape a reality.
00:33 When the body's immune system is working abnormally,
00:36 it can lead to chronic inflammation
00:38 that is extremely damaging.
00:39 Two of the most recognized inflammatory diseases
00:42 are IPF or idiopathic pulmonary fibrosis and lupus.
00:46 IPF and lupus both represent huge markets
00:49 with unmet needs.
00:51 IPF leads of scouring the lungs,
00:53 which makes breathing difficult and painful.
00:55 There are currently no cures and few treatments.
00:58 It was estimated to be a 3.9 billion market in 2022.
01:02 Lupus is an autoimmune disease
01:04 wherein the body essentially attacks itself.
01:06 Like IPF, treatments are limited
01:08 and plagued by side effects.
01:10 The exciting and novel nature of GRI Bio's approach
01:13 and one that could finally bring relief
01:15 to those suffering from IPF and lupus
01:18 centers around NKT cells,
01:20 which are key regulators earlier
01:22 in the inflammatory cascade.
01:23 Specifically, the type one invariant NKT, INKT,
01:27 cells play a critical role in propagating the injury,
01:31 inflammatory response, and fibrosis observed
01:33 in inflammatory and fibrotic indications.
01:36 GRI Bio is focused on developing therapies
01:39 that inhibit INKT cell activity
01:41 to interrupt disease progression
01:43 and restore homeostasis in the immune system.
01:45 The company has a few big years ahead
01:47 with exciting expected milestones,
01:49 some of which are highlighted as follows.
01:52 In the second half of 2023,
01:53 their lead candidate, GRI0621,
01:56 will begin a phase two A biomarker study.
01:59 The data will be announced in 2024.
02:02 In the first half of 2024,
02:03 the IND-enabled studies for GRI0803 will be complete
02:08 and the company will find for IND.
02:11 By the end of 2024,
02:12 results from phase one A and B will be reported.
02:15 These milestones, along with potential of GRI's library
02:18 of over 500 compounds,
02:20 will add to the company's ability
02:21 to fuel a growing pipeline
02:23 and potentially develop new therapies
02:25 for other inflammatory, fibrotic, and autoimmune diseases.
02:29 [MUSIC PLAYING]